Visanne (Dienogest 2mg) Regulatory Post Marketing Surveillance Study in Korea

Trial Profile

Visanne (Dienogest 2mg) Regulatory Post Marketing Surveillance Study in Korea

Completed
Phase of Trial: Phase IV

Latest Information Update: 22 Sep 2017

At a glance

  • Drugs Dienogest (Primary)
  • Indications Endometriosis; Pelvic pain
  • Focus Adverse reactions
  • Sponsors Bayer
  • Most Recent Events

    • 19 Sep 2017 Status changed from active, no longer recruiting to completed.
    • 19 Jun 2017 Planned End Date changed from 30 Jun 2017 to 14 Jul 2017.
    • 19 Jun 2017 Planned primary completion date changed from 30 Jun 2017 to 14 Jul 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top